LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Home・Stock List・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Closed

SectorHealthcare

21.26 3.15

Buy Sell

Overview

Share price change

24h

Current

Min

20.53

Max

21.31

Key metrics
By Trading Economics
Income	258M 216M
Sales	280M 459M
P/E Sector Avg	58.889 80.03
EPS	1.67
Profit margin	47.04
Employees	705
EBITDA	258M 228M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+60.07% upside

Market Stats
By TradingEconomics
Market Cap	-1.1B 2.7B
Previous open	18.11
Previous close	21.26

News Sentiment

By Acuity

50%

167 / 374 Healthcare

Apellis Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Dec 2025, 23:21 UTC

Earnings

Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 Dec 2025, 23:14 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 Dec 2025, 22:01 UTC

Major Market Movers

Costco Wholesale Reports Higher Monthly Sales

3 Dec 2025, 21:38 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 Dec 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 Dec 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 Dec 2025, 23:10 UTC

Earnings

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 Dec 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 Dec 2025, 23:06 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 Dec 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5M

3 Dec 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 Dec 2025, 22:20 UTC

Earnings

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 Dec 2025, 22:19 UTC

Earnings

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 Dec 2025, 22:17 UTC

Earnings

Salesforce Working to Add Voice to Agentforce, CEO Says

3 Dec 2025, 22:16 UTC

Earnings

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 Dec 2025, 22:15 UTC

Earnings

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 Dec 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 Dec 2025, 22:09 UTC

Acquisitions, Mergers, Takeovers

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 Dec 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 Dec 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 Dec 2025, 21:49 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:23 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 Dec 2025, 21:19 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:06 UTC

Earnings

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:04 UTC

Earnings

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 Dec 2025, 21:04 UTC

Earnings

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 Dec 2025, 21:03 UTC

Earnings

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer Comparison

Price change

Apellis Pharmaceuticals Inc Forecast

Price Target

By TipRanks

60.07% upside

12 Months Forecast

Average 33.07 USD 60.07%

High 52 USD

Low 18 USD

Based on 16 Wall Street analysts offering 12 month price targets forApellis Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

16 ratings

Buy

Hold

Sell

Based on 16 analysts giving stock ratings to Apellis Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

167 / 374 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.